Susceptibility Contrast Magnetic Resonance Imaging Determination of Fractional Tumor Blood Volume: A Noninvasive Imaging Biomarker of Response to the Vascular Disrupting Agent ZD6126

International Journal of Radiation Oncology Biology Physics

Volumn 69, Issue 3, 2007, Pages 872-879

  Robinson, Simon P ^a,b   Howe, Franklyn A ^a   Griffiths, John R ^a   Ryan, Anderson J ^c   Waterton, John C ^c  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Biomarker; MRI; Perfusion; USPIO; ZD6126

Indexed keywords

PERFUSION; RELAXATION RATE; TUMOR RESPONSE; TUMOR TISSUE;

BIOMARKERS; BLOOD; HISTOLOGY; IRON OXIDES; MAGNETIC RESONANCE IMAGING; STATISTICAL METHODS;

TUMORS;

BIOLOGICAL MARKER; FERUGLOSE; HOE 33342; N ACETYLCOLCHINOL PHOSPHATE; SODIUM CHLORIDE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VOLUME; CELL STRAIN GH3; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; FIELD FLOW FRACTIONATION; HISTOLOGY; IN VIVO STUDY; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROLACTINOMA; RAT; STATISTICAL SIGNIFICANCE; TISSUE NECROSIS; TISSUE PERFUSION; TISSUE REACTION; TUMOR BLOOD FLOW; TUMOR VOLUME; VASCULAR TUMOR;

ANIMALS; BENZIMIDAZOLES; BLOOD VOLUME; CONTRAST MEDIA; FEMALE; FLUORESCENT DYES; IRON; MAGNETIC RESONANCE IMAGING; ORGANOPHOSPHORUS COMPOUNDS; OXIDES; PITUITARY NEOPLASMS; PROLACTINOMA; RATS;

EID: 34548687690     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.06.061     Document Type: Article

References (51)

1. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
2. Carmeliet P. Angiogenesis in health and disease. Nat Med 9 (2003) 653-660
3. Ferrara N., and Kerbel R.S. Angiogenesis as a therapeutic target. Nature 438 (2005) 967-974
4. Chaplin D.J., and Dougherty G.J. Tumour vasculature as a target for cancer therapy. Br J Cancer 80 (1999) 57-64
5. Siemann D.W., Bibby M.C., Dark G.G., et al. Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 11 (2005) 416-420
6. Tozer G.M., Kanthou C., and Baguley B.C. Disrupting tumour blood vessels. Nature Rev Cancer 5 (2005) 423-435
7. Siemann D.W., Chaplin D.J., and Horsman M.R. Vascular-targeting therapies for treatment of malignant disease. Cancer 100 (2004) 2491-2499
8. Blakey D.C., Westwood F.R., Walker M., et al. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 8 (2002) 1974-1983
9. Davis P.D., Dougherty G.J., Blakey D.C., et al. ZD6126: A novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 62 (2002) 7247-7253
10. Goto H., Yano S., Zhang H., et al. Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice. Cancer Res 62 (2002) 3711-3715
11. Cullis E.R., Kalber T.L., Ashton S.E., et al. Tumour overexpression of inducible nitric oxide synthase (iNOS) increases angiogenesis and may modulate the anti-tumour effects of the vascular disrupting agent ZD6126. Microvasc Res 71 (2006) 76-84
12. Horsman M.R., and Murata R. Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. Int J Radiat Oncol Biol Phys 57 (2003) 1047-1055
13. Robinson S.P., McIntyre D.J.O., Checkley D., et al. Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. Br J Cancer 88 (2003) 1592-1597
14. Evelhoch J.L., LoRusso P.M., He Z., et al. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res 10 (2004) 3650-3657
15. Micheletti G., Poli M., Borsotti P., et al. Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. Cancer Res 63 (2003) 1534-1537
16. Biomarkers Definition Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharm Ther 69 (2001) 89-95
17. McDonald D.M., and Choyke P.L. Imaging of angiogenesis: from microscope to clinic. Nat Med 9 (2003) 713-725
18. Padhani A.R., and Choyke P.L. New techniques in oncologic imaging (2006), Taylor & Francis, Boca Raton, FL
19. Gillies R.J., Raghunand N., Karczmar G.S., et al. MRI of the tumor microenvironment. J Magn Reson Imaging 16 (2002) 430-450
20. Evelhoch J.L., Gillies R.J., Karczmar G.S., et al. Applications of magnetic resonance in model systems: Cancer therapeutics. Neoplasia 2 (2000) 152-165
21. Leach M.O., Brindle K.M., Evelhoch J.L., et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: Issues and recommendations. Br J Cancer 92 (2005) 1599-1610
22. Weissleder R., Elizondo G., Wittenberg J., et al. Ultrasmall superparamagnetic iron oxide: Characterization of a new class of contrast agents for MR imaging. Radiology 175 (1990) 489-493
23. Wu E.X., Tang H., and Jensen J.H. Applications of ultrasmall superparamagnetic iron oxide contrast agents in the MR study of animal models. NMR Biomed 17 (2004) 478-483
24. Robinson S.P., Rijken P.F., Howe F.A., et al. Tumor vascular architecture and function evaluated by non-invasive susceptibility MRI methods and immunohistochemistry. J Magn Reson Imaging 17 (2003) 445-454
25. Tropres I., Grimault S., Vaeth A., et al. Vessel size imaging. Magn Reson Med 45 (2001) 397-408
26. Kostourou V., Robinson S.P., Whitley G.S., et al. Effects of overexpression of dimethylarginine dimethylaminohydrolase on tumor angiogenesis assessed by susceptibility magnetic resonance imaging. Cancer Res 63 (2003) 4960-4966
27. Ferretti S., Allegrini P.R., O'Reilly T., et al. Patupilone induced vascular disruption in orthotopic rodent tumor models detected by magnetic resonance imaging and interstitial fluid pressure. Clin Cancer Res 11 (2005) 7773-7784
28. Robinson S.P., Kalber T.L., Howe F.A., et al. Acute tumor response to ZD6126 assessed by intrinsic susceptibility magnetic resonance imaging. Neoplasia (2005) 466-474
29. Workman P., Twentyman P., Balkwill F., et al. United Kingdom Co-Ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia. Br J Cancer 77 (1998) 1-10
30. Prysor-Jones R.A., and Jenkins J.S. Effect of bromocriptine on DNA synthesis, growth and hormone secretion of spontaneous pituitary tumours in the rat. J Endocrinol 88 (1981) 463-469
31. McPhail L.D., McIntyre D.J.O., Ludwig C., et al. Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis. Neoplasia 8 (2006) 199-206
32. Menke H., and Vaupel P. Effect of injectable or inhalational anesthetics and of neuroleptic, neuroleptanalgesic, and sedative agents on tumor blood flow. Radiat Res 114 (1988) 64-76
33. Kellar K.E., Fujii D.K., Gunther W.H.H., et al. NC100150 injection, a preparation of optimized iron oxide nanoparticles for positive-contrast MR angiography. J Magn Reson Imaging 11 (2000) 488-494
34. Chaplin D.J., Durand R.E., and Olive P.L. Cell selection from a murine tumour using the fluorescent probe Hoechst 33342. Br J Cancer 51 (1985) 569-572
35. Howe F.A., Robinson S.P., Rodrigues L.M., et al. Flow and oxygenation dependent (FLOOD) contrast MR imaging to monitor the response of rat tumors to carbogen breathing. Magn Reson Imaging 17 (1999) 1307-1318
36. * and arterial blood gases. Magn Reson Imaging 19 (2001) 161-166
37. Galbraith S.M., Rustin G.J.S., Lodge M.A., et al. Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 20 (2002) 3826-3840
38. Maxwell R.J., Wilson J., Prise V.E., et al. Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI. NMR Biomed 15 (2002) 89-98
39. Galbraith S.M., Maxwell R.J., Lodge M.A., et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 21 (2003) 2831-2842
40. Dowlati A., Robertson K., Cooney M., et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62 (2002) 3408-3416
41. Thoeny H.C., De Keyzer F., Vandecaveye V., et al. Effect of vascular targeting agent in rat tumor model: dynamic contrast-enhanced versus diffusion-weighted MR imaging. Radiology 237 (2005) 492-499
42. 1H magnetic resonance spectroscopy. Neoplasia 8 (2006) 560-567
43. McPhail L.D., Chung Y.L., Madhu B., et al. Tumor dose response to the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic acid, using in vivo magnetic resonance spectroscopy. Clin Cancer Res 11 (2005) 3705-3713
44. Breidahl T., Nielsen F., Stodkilde-Jorgensen H., et al. The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: A comparative assessment using MRI and MRS. Acta Oncol 45 (2006) 306-316
45. Bjornerud A., Johansson L.O., and Ahlstrom H.K. Pre-clinical results with Clariscan (NC100150 injection); experience from different disease models. MAGMA 12 (2001) 99-103
46. Bentzen L., Vestergaard-Poulsen P., Nielsen T., et al. Intravascular contrast agent-enhanced MRI measuring contrast clearance and tumor blood volume and the effects of vascular modifiers in an experimental tumor. Int J Radiat Oncol Biol Phys 61 (2005) 1208-1215
47. Turetschek K., Huber S., Floyd E., et al. MR imaging characterization of microvessels in experimental breast tumors by using a particulate contrast agent with histopathologic correlation. Radiology 218 (2001) 562-569
48. Rydland J., Bjornerud A., Haugen O., et al. New intravascular contrast agent applied to dynamic contrast enhanced MR imaging of human breast cancer. Acta Radiol 44 (2003) 275-283
49. Dennie J., Mandeville J.B., Boxerman J.L., et al. NMR imaging of changes in vascular morphology due to tumor angiogenesis. Magn Reson Med 40 (1998) 793-799
50. Fan X., River J.N., Zamora M., et al. Differentiation of nonmetastatic and metastatic rodent prostate tumors with high spectral and spatial resolution MRI. Magn Reson Med 45 (2001) 1046-1055
51. Siemann D.W., and Rojiani A.M. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 53 (2002) 164-171